Oscar Health (OSCR) Cash & Equivalents (2020 - 2026)

Oscar Health (OSCR) has 7 years of Cash & Equivalents data on file, last reported at $4.8 billion in Q1 2026.

• Quarterly Cash & Equivalents rose 114.85% year-over-year to $4.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.8 billion (up 114.85% YoY) and the FY2025 annual result came in at $2.8 billion, up 81.65% from the prior year.
• Cash & Equivalents climbed to $4.8 billion in Q1 2026, from $2.8 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 billion in Q1 2026 to a low of $1.2 billion in Q3 2024.
• A 5-year average of $2.2 billion and a median of $2.1 billion in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents tumbled 33.75% — and 2026, when it jumped 114.85%.
• Tracing OSCR's Cash & Equivalents over 5 years: stood at $1.6 billion in 2022, then climbed by 20.0% to $1.9 billion in 2023, then fell by 18.35% to $1.5 billion in 2024, then soared by 81.65% to $2.8 billion in 2025, then surged by 73.21% to $4.8 billion in 2026.
• The last three Cash & Equivalents figures came in at $4.8 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.